Daily Updates
Congress Opens a China Trials Probe Into the Five Biggest Pharmas
Back on June 3, when Pfizer and Lilly both signed China deals on the same day, we wrote that the political rhetoric said decouple while
Your fast, high-signal look at everything that moved biotech, medtech, and pharma today. The BioMed Nexus Daily Update delivers the most important regulatory moves, trial readouts, deals, and industry developments in one concise, easy-to-scan report. Updated every weekday morning.
Back on June 3, when Pfizer and Lilly both signed China deals on the same day, we wrote that the political rhetoric said decouple while
The Tavneos story keeps getting worse, and it now raises a question that should concern every company with a marketed drug: how quickly can a
The obesity market grew up today. When the Medicare GLP 1 Bridge goes live, it marks the shift from the era of scarcity to the
The M&A wave is no longer just a big pharma story. Monday brought two more deals, but neither came from the usual mega cap buyers.
Replimune’s RP1 received two complete response letters from the FDA. Two rejections. Most companies would have shelved the program and moved on. Instead, Replimune resubmitted,
If you work in a pharma or biotech lab, you have used Bio Techne products. The recombinant proteins that populate your assay panels. The antibodies
This is the gene therapy story nobody wanted but everybody expected. Sangamo Therapeutics, which pioneered zinc finger nuclease technology and built one of the earliest
Pfizer paid $43 billion for Seagen in 2023 to become an ADC powerhouse. The deal brought in Padcev (bladder cancer), Adcetris (lymphoma), and Tivdak (cervical
AbbVie knows immunology better than almost anyone. Humira made the company more than $200 billion before it went off patent. Skyrizi and Rinvoq are growing
Last Wednesday, Biogen executives told Fierce Biotech the company was becoming “the new Biogen” through external partnerships and acquisitions. Five days later, the company wrote